NCT04693533View on ClinicalTrials.gov

Fremanezumab, Migraine and Sleep

PHASE4RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

July 29, 2021

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2025

Conditions

Migraine DisordersSleep Disorder

Interventions

DRUG

Fremanezumab Prefilled Syringe [Ajovy]

The treatment is 225 mg (dissolved in 1.5 ml saline) fremanezumab. Fremanezumab (Ajovy) is a month-long-acting anti-CGRP injection that patients are taught to self-administer at home.

Trial Locations (1)

02215

RECRUITING

BIDMC Headaceh Clinic, Boston

All Listed Sponsors

collaborator

Teva Pharmaceuticals USA

INDUSTRY

lead

Beth Israel Deaconess Medical Center

OTHER

NCT04693533 - Fremanezumab, Migraine and Sleep | Biotech Hunter | Biotech Hunter